Reference,Reference: DOI,Assay,Section,Pre-vaccine Infection,Vaccine,# Shots,Months,Host,Control,Control: NT50 Cmp,Control: NT50 GeoMean,Control: NT50 GSD,Variant,Variant: Pos,Variant: Mutations,# Results,Potency: NT50 Cmp,Potency: NT50 GeoMean,Potency: NT50 GSD,Fold Reduction: Cmp,Fold Reduction: Median
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,984.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1043.0,1.0,=,0.9
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,972.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,703.0,1.0,=,1.4
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,774.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,544.0,1.0,=,1.4
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,509.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,443.0,1.0,=,1.1
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,1038.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,1014.0,1.0,=,1.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,990.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,968.0,1.0,=,1.0
Tada21e,10.3389/fimmu.2022.797589,Pseudovirus (HIV),Supplementary Table 2,None,mRNA-1273,2,2-6m,Human,Wild Type (B.1),=,537.0,1.0,Alpha,69,Δ69-70 + Δ141 + Δ144-145 + N501Y + A570D + P681H + T716I + S982A + D1118H,1,=,485.0,1.0,=,1.1